ACE-031

ACE-031 is a soluble decoy receptor fusion protein consisting of the extracellular domain of activin type IIA receptor (ActRIIA) linked to a human IgG1 Fc region, developed by Acceleron Pharma to bind and sequester myostatin, activin, and related TGF-beta superfamily ligands that negatively regulate muscle mass, with the goal of promoting muscle growth in severe wasting conditions including Duchenne muscular dystrophy. By competitively binding circulating myostatin and related ligands, ACE-031 reduces signaling through the Smad2/3 pathway that suppresses muscle satellite cell activation and protein synthesis; in preclinical models of myopathy, blockade of ActRIIA signaling produced significant increases in lean mass, supporting its evaluation in Phase 2 human trials.

myostatin/activin inhibition, muscle mass increase, bone density improvement.

Research on ACE-031 primarily documents effects related to myostatin/activin inhibition and muscle mass increase and bone density improvement. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

Reported contraindications and considerations for ACE-031 include cardiovascular disease, telangiectasia risk, bleeding disorders. 1 additional consideration are noted in the safety profile above. This is educational information only — consult a qualified healthcare professional before use.

For ACE-031, its FDA status is investigational (not FDA-approved), and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

4 providers in the directory currently offer ACE-031.

Across 8 research vendors tracked on PeptideBase, ACE-031 has a median price of about $119.00 per mg, typically ranging $78.70–$161.50 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.

In a phase 1/2 randomized placebo-controlled trial of ACE-031 in boys with Duchenne muscular dystrophy, subcutaneous administration showed trends toward maintaining 6-minute walk test distance and increasing lean body mass and bone mineral density, though the study was discontinued early due to non-muscle-related safety signals including epistaxis and telangiectasias.